Suivre
Patrick K Tumwebaze
Patrick K Tumwebaze
Molecular Parasitology Research lab Manager, Infectious Diseases Research Collaboration, Uganda
Adresse e-mail validée de idrc-uganda.org
Titre
Citée par
Citée par
Année
Changing prevalence of potential mediators of aminoquinoline, antifolate, and artemisinin resistance across Uganda
V Asua, MD Conrad, O Aydemir, M Duvalsaint, J Legac, E Duarte, ...
The Journal of infectious diseases 223 (6), 985-994, 2021
1562021
Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance
LA Kirkman, W Zhan, J Visone, A Dziedziech, PK Singh, H Fan, X Tong, ...
Proceedings of the National Academy of Sciences 115 (29), E6863-E6870, 2018
802018
Lack of artemisinin resistance in Plasmodium falciparum in Uganda based on parasitological and molecular assays
RA Cooper, MD Conrad, QD Watson, SJ Huezo, H Ninsiima, ...
Antimicrobial agents and chemotherapy 59 (8), 5061-5064, 2015
762015
The impact of antimalarial resistance on the genetic structure of Plasmodium falciparum in the DRC
R Verity, O Aydemir, NF Brazeau, OJ Watson, NJ Hathaway, ...
Nature communications 11 (1), 2107, 2020
732020
Impact of antimalarial treatment and chemoprevention on the drug sensitivity of malaria parasites isolated from Ugandan children
P Tumwebaze, MD Conrad, A Walakira, N LeClair, O Byaruhanga, ...
Antimicrobial agents and chemotherapy 59 (6), 3018-3030, 2015
652015
Changing antimalarial drug sensitivities in Uganda
SA Rasmussen, FG Ceja, MD Conrad, PK Tumwebaze, O Byaruhanga, ...
Antimicrobial agents and chemotherapy 61 (12), 10.1128/aac. 01516-17, 2017
632017
Changing antimalarial drug resistance patterns identified by surveillance at three sites in Uganda
P Tumwebaze, S Tukwasibwe, A Taylor, M Conrad, E Ruhamyankaka, ...
The Journal of infectious diseases 215 (4), 631-635, 2017
552017
Evolution of partial resistance to artemisinins in malaria parasites in Uganda
MD Conrad, V Asua, S Garg, D Giesbrecht, K Niaré, S Smith, ...
New England Journal of Medicine 389 (8), 722-732, 2023
532023
Tools for mass screening of G6PD deficiency: validation of the WST8/1-methoxy-PMS enzymatic assay in Uganda
M De Niz, AC Eziefula, L Othieno, E Mbabazi, D Nabukeera, ...
Malaria journal 12, 1-11, 2013
432013
Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and lumefantrine in northern Uganda
PK Tumwebaze, MD Conrad, M Okitwi, S Orena, O Byaruhanga, T Katairo, ...
Nature communications 13 (1), 6353, 2022
412022
Drug susceptibility of Plasmodium falciparum in eastern Uganda: a longitudinal phenotypic and genotypic study
PK Tumwebaze, T Katairo, M Okitwi, O Byaruhanga, S Orena, V Asua, ...
The Lancet Microbe 2 (9), e441-e449, 2021
382021
The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance
JM Murithi, C Pascal, J Bath, X Boulenc, NF Gnädig, CFA Pasaje, ...
Science translational medicine 13 (603), eabg6013, 2021
322021
Validation of the ligase detection reaction fluorescent microsphere assay for the detection of Plasmodium falciparum resistance mediating polymorphisms in Uganda
S Nankoberanyi, GW Mbogo, NP LeClair, MD Conrad, P Tumwebaze, ...
Malaria journal 13, 1-5, 2014
322014
Potent antimalarials with development potential identified by structure-guided computational optimization of a pyrrole-based dihydroorotate dehydrogenase inhibitor series
MJ Palmer, X Deng, S Watts, G Krilov, A Gerasyuto, S Kokkonda, ...
Journal of medicinal chemistry 64 (9), 6085-6136, 2021
302021
Impact of Intermittent Preventive Treatment During Pregnancy on Plasmodium falciparum Drug Resistance–Mediating Polymorphisms in Uganda
MD Conrad, D Mota, M Foster, S Tukwasibwe, J Legac, P Tumwebaze, ...
The Journal of infectious diseases 216 (8), 1008-1017, 2017
302017
Intermittent preventive treatment with dihydroartemisinin-piperaquine in Ugandan schoolchildren selects for Plasmodium falciparum transporter polymorphisms that modify drug …
JI Nankabirwa, MD Conrad, J Legac, S Tukwasibwe, P Tumwebaze, ...
Antimicrobial agents and chemotherapy 60 (10), 5649-5654, 2016
302016
Improvement of Asparagine Ethylenediamines as Anti-malarial Plasmodium-Selective Proteasome Inhibitors
W Zhan, J Visone, T Ouellette, JC Harris, R Wang, H Zhang, PK Singh, ...
Journal of medicinal chemistry 62 (13), 6137-6145, 2019
292019
Fitness Consequences of Plasmodium falciparum pfmdr1 Polymorphisms Inferred from Ex Vivo Culture of Ugandan Parasites
E Ochong, PK Tumwebaze, O Byaruhanga, B Greenhouse, PJ Rosenthal
Antimicrobial agents and chemotherapy 57 (9), 4245-4251, 2013
232013
Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti‐malaria Activity in Humanized Mice
W Zhan, H Zhang, J Ginn, A Leung, YJ Liu, M Michino, A Toita, ...
Angewandte Chemie 133 (17), 9365-9369, 2021
222021
Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183
LE de Vries, PAM Jansen, C Barcelo, J Munro, JMJ Verhoef, CFA Pasaje, ...
Nature communications 13 (1), 2158, 2022
212022
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20